1Polizzi D, Pratesi G, Tortoreto M, et al. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts[J]. Cancer Res, 1999, 59(5):1036- 1340.
2Edwards ML, Stemerick DM, Sunkara PS. Chalcones: a new class of antimitotic agents[ J]. J Med Chem, 1990, 33(7): 1948 - 1954.
3Silence K, D'Hoore A, Englborghs Y, et al. Fluorescence stopped-flow study of the interaction of tubulin with the antimitotic drug MDL27048 [ J ]. Biochemistry, 1992, 31(45):11133- 11137.
4Wheeler GP, Bowdon BJ, Temple C Jr, et al. Biological effects and structure-activity relationships of 1,2-dihydropyrido[3,4-b] pyrazines[J]. Cancer Res, 1983, 43(8):3567- 3575.
5de Ines C, Leynadier D, Barasoain I, et al. Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumour drug, GI-980, and by its chiral isomer, NSC613863[J]. Cancer es, 1994, 54(1):75-84.
6Raynaud FI, Kelland LR, Walton MI, et al. Preclinical pharmacology of 1069C85, a novel tubulin binder [ J].Cancer Chemother Pharmacol, 1994, 35(2):169- 173.
7Jiang JD, Rohoz J, Weisz I, et al. Synthesis, cancericidal and antimicrotubule activities of 3-(haloacetamido)-benzoylureas[J]. Anticancer Drug Des, 1998, 13(7):735 -747.
8Li JN, Song DQ, Lin YH, et al. Inhibition of microtubule polymerization by 3-bromopropionylamino benzoylurea (JIMB01), a new cancericidal tubulin ligand[J]. Biochem Pharmacol, 2003, 65(10):1691-1699.
9Okada H, Koyanagi T, Yamada N, et al. Synthesis and antitumor activities of novel benzoylphenylurea derivatives[J]. Chem Pharm Bull(Tokyo), 1991, 39(9):2308-2315.
10Ando N, Nakajima T, Masuda H, et al. Antimicrotubule effects of the novel antitumor benzoylphenylurea derivative HO-221[J]. Cancer Chemother Pharmacol, 1995, 37(1/2):63-68.
